(Q24235303)

English

Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children (English)

0 references

0 references

Francine M Ducharme

1

object named as

Francine M Ducharme

0 references

author name string

Muireann Ni Chroinin

2

0 references

Ilana Greenstone

3

0 references

Toby J Lasserson

4

0 references

language of work or name

0 references

publication date

2010

0 references

Cochrane Database of Systematic Reviews

0 references

5

0 references

CD005535

0 references

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Regular treatment with salmeterol for chronic asthma: serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Simpson's paradox and calculation of number needed to treat from meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Regular treatment with formoterol for chronic asthma: serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Fluticasone versus placebo for chronic asthma in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Ciclesonide versus placebo for chronic asthma in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

19 March 2017

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

7 April 2017

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): introduction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Innovative therapies for asthma: anti-IgE -- the future?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Efficacy and tolerability of formoterol Turbuhaler in children.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Clinical trials: are these your patients?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effect of long‐acting β2 agonists on exacerbation rates of asthma in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromogl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Formoterol delivered by Turbuhaler: in pediatric asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Treatment of bronchial asthma using a new adjustable combination treatment plan: Asthma Control Plan (ATACO)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effectiveness and safety of salmeterol in nonspecialist practice settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol in paediatric asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol xinafoate in children on high dose inhaled steroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Validation of an asthma quality of life diary in a clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Estimation of a common effect parameter from sparse follow-up data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

27 September 2017

Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Salmeterol in the treatment of chronic asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Models for estimating the number of unpublished studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Inhaled formoterol during one year in asthma: a comparison with salbutamol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

30 May 2018

Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Development of an economic model to assess the cost effectiveness of asthma management strategies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma☆☆☆★★★

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Formoterol protects against platelet-activating factor-induced effects in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Long-acting bronchodilators in premenstrual exacerbation of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of the effects of salmeterol and formoterol in patients with severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

What is a spontaneous pneumothorax?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

A double-blind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535.PUB2

21 January 2018

Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

The correlation between asthma control and health status: the GOAL study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Fixed-dose fluticasone-salmeterol combination: at least effective and better tolerated than open-dose combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Control of asthma by treatment with inhaled corticosteroids and prolonged action beta 2-agonists in free or fixed combination. Results of the ALISE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Beta(2)-agonists: déjà vu all over again: the second-generation controversy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

MIASMA: asthma exacerbation reduction with salmeterol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

The effect of triamcinolone, montelukast and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Continuing patient care with metered-dose inhalers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Clinical evaluation of CFC-free metered dose inhalers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169792

29 November 2018

Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of budesonide on the response to inhaled terbutaline in children with mild asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of salmeterol in childhood asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of treatment with formoterol on bronchoprotection against methacholine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of salmeterol is independent of previously inhaled salbutamol: a clinical controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Salmeterol improves control in asthmatic patients treated in general practice. A comparative study of salmeterol (Serevent) and salbutamol (Ventoline) in patients with mild to moderate asthma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol compared with current therapies in chronic asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled Salmeterol and Albuterol in Asthmatic Patients Receiving High-dose Inhaled Corticosteroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of salmeterol in the maintenance treatment of asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Long-term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beta-adrenergic bronchodilators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of anti-asthmatic drugs on the response to inhaled endotoxin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Need for theophylline in severe steroid-requiring asthmatics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24235303&oldid=1623182895"